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Verfaille, Brad Wouters, Daniel Zips).Access to modern radiation oncology treatment programmes is now recognised as an essential compo-
nent of high-quality cancer treatment and central to optimal patient care. Looking to the future, ESTRO
strongly believes that further development of the discipline will be critically important to the future stra-
tegic development of multidisciplinary cancer care. On behalf of the Board and membership of ESTRO,
this document outlines the Society’s Vision for the development of the discipline of Radiation and Clinical
Oncology together with the associated priority action areas that will collectively and strategically direct
the Society’s activities in the forthcoming years.
 2012 Published by Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.Radiotherapy and Oncology 103 (2012) 99–102The recent celebration of ESTRO’s 30th anniversary marked a
very important opportunity to acknowledge and celebrate three
decades of achievement, growth and scientiﬁc progress for the
Society and the clinical discipline of Radiation and Clinical Oncol-
ogy. Since the foundation of ESTRO, Radiation Oncology has fortu-
nately seen continuous change with virtually every aspect of the
basic science of our discipline and clinical treatment dramatically
improving to the beneﬁt of patient care. This progress is epito-
mized by the numerous innovative developments in treatment
equipment, new delivery technologies and associated imaging
modalities, that collectively have enabled patient access to
highly-optimised precision radiation therapy, together with the
remarkable advances in our understanding of the biological basis
of radiation effect, and most recently the emerging use of novel
molecularly targeted therapeutics that holds the promise of further
substantial improvements in tumour control and patient cure.
As the Society looks forward to further advances in the disci-
pline, it is timely for the Society and for the ﬁrst time to document
ESTRO’s Vision for the future of Radiation Oncology and the associ-
ated priorities that ESTRO will champion to enable this Vision. Intini).
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Open access under CC BY-NC-ND licensorder to achieve this goal and in parallel with the recent updating
of the ESTRO Articles of Association and internal rules of proce-
dure, the ESTRO Board assisted by representative Society Ofﬁcers
and ESTRO Standing Committee members, recently completed a
strategic review of the anticipated future changes in Radiation
Oncology clinical practice, and importantly the strategic role of
ESTRO in assisting such developments. As a direct result of this
meeting, the following article describes ESTRO’s Vision for
Radiation Oncology and cancer care. Within this document the
Society has stated a Primary Vision that unequivocally links the
development of optimal patient care to equitable patient access
to state of the art radiation therapy. In addition, important
subsidiary Vision Statements (1.1–1.5) are stated that in turn
specify the future priorities that will shape and inﬂuence the
direction of Society’s activities in the forthcoming years.
It is important to highlight that ESTRO will seek to champion
this Vision and associated priorities as an interdisciplinary Society,
and that the Society will work to achieve this objective in partner-
ship with the wide range of existing and future organisations that
are collectively assisting the development of future multidisciplin-
ary cancer care, including where appropriate other scientiﬁc and
professional societies, international agencies, national representa-
tive groups, collaborative clinical trials groups, and patient advo-
cacy groups. In addition the Society will develop new areas of
engagement with regulatory authorities including the European
Union (EU), European Economic Area (EEA), and national regula-
tory agencies, and together with non-governmental organisations
(NGO’s) assist the broader development of Radiation Oncology as
part of the evolution of different models of cancer care within indi-
vidual European countries. Finally, we believe that this document
will assist all Society members in collectively supporting the Soci-
ety’s Vision for the future development and growth of Radiation
and Clinical Oncology both within Europe and at a global level in
the forthcoming decades.e.
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Vision
Every cancer patient in Europe will have access to state of the
art radiation therapy, as part of a multidisciplinary approach where
treatment is individualised for the speciﬁc patient’s cancer, taking
account of the patient’s personal circumstances.
Vision 1.1: Optimal individualised patient care will be achieved
by integrating, new clinical and preclinical evidence from biol-
ogy, molecular/functional and anatomic imaging, and the use of
novel systemic agents together with the delivery of high-preci-
sion radiation therapy in a safety-aware environment.
Vision 1.2: The majority of patients will live cancer free with
minimal toxicity following the use of radical radiation therapy
when used as a single curative modality of treatment or when
used in combination with surgery, systemic chemotherapy
and/or systemic targeted therapeutics.
Vision 1.3: Access to continuing medical education (CME) and
continuing professional and personal development (CPPD) will
empower both healthcare professionals and patients to fully
participate in all decisions regarding treatment.
Vision 1.4: National and international policy-makers, healthcare
management, industrial and corporate partners, and other pro-
fessional oncology societies will recognise radiation oncology as
a major contributor to cancer cure, and ESTRO as a strategic
driving force in the multidisciplinary ﬁght against cancer.
Vision 1.5: ESTRO will take all reasonable measures to further
develop as the preeminent educational and scientiﬁc society
in Radiotherapy and Oncology, and through this role, the Soci-
ety will have a unique strategic responsibility for the future
development of the clinical discipline of Radiation and Clinical
Oncology within Europe and at a global level.
ESTRO Vision – Radiation Oncology and Patient Care
Every cancer patient in Europe will have access to state of the
art radiation therapy, as part of a multidisciplinary approach where
treatment is individualised for the speciﬁc patient’s cancer, taking
account of the patient’s personal circumstances.
In order to achieve this vision ESTRO will support the following
initiatives and model of clinical care as part of the future strategic
development of the Society:
1. All patients are entitled to access healthcare systems that
enable the highest quality radiotherapy delivered within a safe
healthcare environment, and on completion of treatment have
access to appropriate long term follow-up, advice and support
from members of the clinical radiation oncology team.
2. All patients are entitled to receive full information on the pri-
mary beneﬁt, and where unavoidable, the potential side effects
associated with their proposed radiation therapy treatment
programme.
3. For all patients receiving radiation therapy, the patient–doctor
relationship will continue to be of central importance, and this
will remain a critical requirement in the future development of
the clinical discipline of radiation oncology.
4. In recognition of the multidisciplinary nature of radiation
oncology the patient will signiﬁcantly beneﬁt from the
additional expert input from other members of the radiation
oncology multidisciplinary team and allied healthcare
disciplines.
5. Given the critical role of radiation therapy in the care of individ-
ual patients, the radiation oncologist will frequently be the lead
physician responsible for the overall care of the patient, andtherefore have a unique responsibility for the patients’ on-going
care and wellbeing.
6. In recognition of the above, ESTRO will continue to develop
innovative mechanisms that enable young professionals within
the Society and in radiation oncology to actively participate in
the development of future clinical services for patients, in par-
ticular through the strategic development of scientiﬁc, educa-
tional and professional services coordinated by the Society.
ESTRO Vision and priorities for the development of Radiation
Oncology
Vision 1.1
Optimal individualised patient care will be achieved by inte-
grating new clinical and preclinical evidence from biology, molec-
ular/functional and anatomic imaging and the use of new systemic
agents together with the delivery of high precision radiation
therapy in a safety aware environment.
In order to achieve this vision ESTRO will enable and support
the following priorities:
(a) ESTRO will provide strategic leadership on the emerging and
future approaches that will enable further improvements in
the physical and biological optimisation of radiation
therapy.
(b) ESTRO will support the need for a unique range of healthcare
professionals, working as an interdisciplinary team, to be
centrally involved in the delivery of all clinical, physical,
technical and biological aspects of radiation therapy.
(c) ESTRO will in addition and where appropriate support the
central role of radiation and clinical oncologists in taking full
clinical responsibility for the delivery, supervision and mon-
itoring of patients receiving combined-modality treatments
using radiation and either cytotoxic and/or targeted
therapeutics.
(d) ESTRO will facilitate its members in creating collaborations,
clinical studies and collaborative research that enable the
exchange of ideas, the development of new interdisciplinary
networks, and novel approaches to the future individualisa-
tion of radiation oncology.
(e) In support of the above, ESTRO will establish a forum where
codes of practice, guidelines, education, and professional
development resources are easily accessible and tailored to
the professional needs of the membership of the Society.
Vision 1.2
The majority of patients will live cancer free with minimal tox-
icity following the use of radical radiation therapy when used as a
single curative modality of treatment or when used in combination
with surgery, systemic chemotherapy and/or systemic targeted
therapeutics.
In order to achieve this vision ESTRO will enable and support
the following priorities:
(a) ESTRO will support new developments in radiation oncology
that further improve the biological optimisation, physical
delivery and safety of high-precision radiotherapy, enhanc-
ing the potential for optimal tumour control, and offering
the opportunity for improved treatments with curative and
organ-preserving intent.
(b) ESTRO will support the further investigation of high-preci-
sion radiotherapy used with curative intent in patients with
metastatic and locally recurrent disease, with the objective
of obtaining the necessary evidence-base for this approach,
and the future development of innovative clinical
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special patient population.
(c) To enable the above improvements in clinical care, ESTROwill,
through its congress, specialmeetings, educational coursesand
journal(s), support the future development of radiation oncol-
ogy, emphasising and supporting the need for the following:
 New approaches to adaptive radiotherapy integrating
novel developments in biology, imaging, technology, and
the assessment of tumour response and patient outcome.
 Innovative research and development on the potential
future use of novel biological modiﬁers of tumour and
normal tissue response.
 The development of validated predictive models of treat-
ment outcome based on complex databases comprising
clinical, biologic, genetic, imaging, dosimetric and popu-
lation data.
 The continued development of quality programmes,
including clinical audit and comprehensive safety sys-
tems in Radiation and Clinical Oncology that maintain
the principles of providing the highest quality of patient
care and treatment in a safety-aware enviroment.Vision 1.3
Access to continued medical education (CME) and continued
professional and personal development (CPPD) will empower both
healthcare professionals and patients to fully participate in all
decisions regarding treatment.
In order to achieve this vision ESTRO will enable and support
the following priorities:
(a) ESTRO will promote and publish journal(s) and where
appropriate additional supplementary information of the
highest scientiﬁc quality and through this approach set the
existing and future standards for the specialty.
 The purpose of the Society’s journal, Radiotherapy &
Oncology, will be to provide, for members of the Society
and all radiation oncology professionals, access to high-
est-level scientiﬁc information thereby enabling the
accelerated development of new treatment approaches
and the practice of evidence-based radiation oncology.
 In addition, the Society will create new web-based plat-
forms to enhance the accessibility of ESTRO’s related pol-
icy statements and documentation including Society
guidelines, curricula, educational publications, confer-
ence proceedings, and strategic policy statements devel-
oped by the Society or in partnership with other
European professional cancer organisations.(b) ESTRO will in addition facilitate and enhance the dissemina-
tion of science through an expanded portfolio of meetings
and educational courses including:
 Congresses focusing on integrated interdisciplinary/mul-
tidisciplinary approaches.
 Organ and technical oriented conferences, meetings and
workshops.
 Discipline oriented research conferences, meetings and
workshops.
 Health economic research conferences, meetings and
workshops.
 Conferences addressing new horizons and blue-sky
research in radiation oncology.
 The further development of links and strategic partner-
ships with national radiation oncology societies.
 The further development of basic and advanced educa-
tional courses through the established ESTRO School of
Radiotherapy and Oncology.Vision 1.4
National and international policy-makers, healthcare manage-
ment, industrial & corporate partners, and other professional
oncology societies will recognise radiation oncology as a major
contributor to cancer cure, and ESTRO as a strategic driving force
in the multidisciplinary ﬁght against cancer.
In order to achieve this vision ESTRO will enable and support
the following priorities:
(a) ESTRO will take all necessary measures to promote and
advance multidisciplinary networking and onco-policy
through a comprehensive, active and strategic partnership
within ECCO.
(b) ESTRO will take a leadership role in advising the European
Union (EU), European Commission (EC) and European Eco-
nomic Area (EEA) on the future strategic development of
all matters relating to the clinical discipline of radiation
oncology within Europe.
(c) ESTRO will examine the opportunities to liaise and develop
collaborative partnerships with other European and Interna-
tional agencies and societies, in particular with those groups
that directly work in, or advise on the ﬁeld of radiation
oncology, including the Union Européenne des Médecins
Spécialistes (UEMS) Section of Radiotherapy and the Interna-
tional Atomic Energy Agency (IAEA).
(d) ESTRO will where appropriate take a similar leadership role
in advising the wide range of international health agencies,
intergovernmental groups and non governmental organisa-
tions (NGOs) on the future strategic development of radia-
tion oncology at a global level.
(e) In recognition of the need to strengthen partnerships with
industry, ESTRO will become a driving force in shaping and
guiding collaborations between radiation oncology and
industry, particularly with respect to product development
pathways for equipment, pharmaceutical and biotechnology
sectors in the ﬁeld of radiation oncology.
(f) To enable this partnership, the Society will create new and
innovative platforms to support and foster collaboration
with industry and thereby strengthen the synergy between
the Society and industrial/corporate partners.
Vision 1.5
ESTRO will take all reasonable measures to further develop as
the preeminent scientiﬁc society in Radiotherapy and Oncology,
and through this role, the Society will have a unique long-term
strategic responsibility for the future development of the clinical
discipline of Radiation and Clinical Oncology within Europe and
at a global level.
In order to facilitate this vision ESTRO will enable and support
the following new priorities:
(a) ESTRO will examine newmodels of membership that further
strengthen the range of education, training and professional
services available to Society members including:
 The feasibility of modiﬁed annual membership fees for
young members.
 The development of new forms of multi-year member-
ship for existing members.
 The potential for new membership models linking
national radiation oncology groups and the Society.
(b) ESTRO will create a dedicated communication hub within
the ofﬁce, for the beneﬁt of Society members, national soci-
eties and other professional oncology and scientiﬁc societies
that will support and facilitate the wide range of issues that
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issues arising from meetings and activities of the Profes-
sional and Membership Council, Scientiﬁc Council, Executive
Council and Board of the Society.
(c) ESTRO will further support the development of innovative
health services research in radiotherapy and oncology,
including the long term analysis of changes in specialist
stafﬁng in the discipline, the level of equipment, the appro-
priate implementation of new technology, patient access to
new treatment approaches; together with the critical analy-
sis of these strategic developments using cost-beneﬁt, cost-
utility and other means of health economic review and
health technology assessment (HTA). In the ﬁrst instance
ESTRO has initiated this strategic priority through the crea-
tion of the Health Economics in Radiation Oncology (HERO)
project.
(d) ESTRO acknowledges that whilst differences exist in the
state of development of radiotherapy and clinical oncol-
ogy in individual countries within Europe, the Society
together with national societies will create and prioritise
innovative strategic partnerships in order to strengthen
the clinical and scientiﬁc specialty in the respective
countries and in addition to support an increased level
of patient care and quality of treatment throughout
Europe.
(e) ESTRO will investigate and strengthen its relationship with
European and international cooperative clinical trials organ-
isations, national clinical trials groups, and where appropri-
ate individual cancer centres and hospitals, with a view to
supporting such clinical trials, related clinical and transla-
tional research including: The presentation of such research at the full range of sci-
entiﬁc meetings coordinated by ESTRO, especially the
ESTRO forum and ESTRO meeting within ECCO.
 The prioritised publication of such trials in the Society
journal(s).(f) ESTRO will develop and enhance its web-based portfolio of
resources to the beneﬁt of all members, taking full account
of the future strategic potential of new developments in
information and communication technology.
(g) Recognising the strategic importance of young members to
the development and future of ESTRO and the clinical disci-
pline of radiation oncology, the ESTRO Board will continue to
prioritise initiatives to increase young member participation
in the Society including:
 Enhanced opportunities for radiation oncologists, physi-
cists, RTT’s, biologists, nurses and allied heath profession-
als training in the ﬁeld of radiation oncology to become
full active members of ESTRO.
 The examination of new approaches to enable innovative
international exchange programmes for young ESTRO
members.
 The expansion and further development of the ESTRO
Fellow programme.
 The further development of young membership involve-
ment in teaching courses, specialist meetings, and the
ESTRO meeting, ESTRO Forum and ECCO meetings.
 The strategic involvement of young members in speciﬁc
committees, task groups and special meetings organised
by the Society.
